Seres Therapeutics (MCRB) EBITDA Yield: History & Chart

Seres Therapeutics, Inc.(MCRB)

Biotechnology · Cambridge, MA

$2.91+0.06 (+2.21%)

Delayed quote: Oct 6, 2026, 3:45 PM EDT

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Cambridge, MA

66 employees

www.serestherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard N. Kender

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Seres Therapeutics, Inc. (MCRB)	$28.21M	N/A	N/A	N/A	N/A
aTyr Pharma, Inc. (ATYR)vs ›	$27.92M	N/A	N/A	N/A	N/A
OneMedNet Corporation (ONMD)vs ›	$28.73M	N/A	N/A	N/A	N/A
Tevogen Bio Holdings Inc. (TVGN)vs ›	$28.86M	N/A	N/A	N/A	N/A
GridAI Technologies Corp. (GRDX)vs ›	$29.17M	N/A	N/A	N/A	N/A
BeyondSpring Inc. (BYSI)vs ›	$29.20M	N/A	N/A	N/A	N/A
Context Therapeutics Inc. (CNTX)vs ›	$29.37M	N/A	N/A	N/A	N/A
Quantum Cyber N.V. (QUCY)vs ›	$29.60M	N/A	N/A	N/A	N/A
Rockwell Medical, Inc. (RMTI)vs ›	$29.80M	N/A	5.17%	5.17%	5.17%
MIRA Pharmaceuticals, Inc. (MIRA)vs ›	$30.17M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Seres Therapeutics, Inc. (MCRB)

$28.21M

N/A

aTyr Pharma, Inc. (ATYR)vs ›

$27.92M

N/A

OneMedNet Corporation (ONMD)vs ›

$28.73M

N/A

Tevogen Bio Holdings Inc. (TVGN)vs ›

$28.86M

N/A

GridAI Technologies Corp. (GRDX)vs ›

$29.17M

N/A

BeyondSpring Inc. (BYSI)vs ›

$29.20M

N/A

Context Therapeutics Inc. (CNTX)vs ›

$29.37M

N/A

Quantum Cyber N.V. (QUCY)vs ›

$29.60M

N/A

Rockwell Medical, Inc. (RMTI)vs ›

$29.80M

N/A

5.17%

MIRA Pharmaceuticals, Inc. (MIRA)vs ›

$30.17M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

MCRB EBITDA Yield Metrics

MCRB Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics